10-Q quarterly report · filed Oct 29, 2026

Insmed Incorporated (INSM) Q3 2026 10-Q Quarterly Report

Short answer

Insmed Incorporated (INSM) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $524M (up 268.4% year over year) with net income of −$100M.

Q3 2026 key financials · XBRL

Revenue
$524M
+268.4% YoY · +23.3% QoQ
Net income
−$100M
+72.9% YoY · −657.6% QoQ
Operating margin
-17.0%
EPS (diluted)
−$0.46
+74.0% YoY · −666.7% QoQ

Source: XBRL data from the Insmed Incorporated (INSM) Q3 2026 10-Q on SEC EDGAR. USD.

Insmed Incorporated Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $524.4M, up $382.1M or 268% YoY, driven by BRINSUPRI
  • BRINSUPRI revenue $400.1M vs $28.1M, while ARIKAYCE revenue rose 9% to $124.4M
  • Cost margin 85.1% vs 79.4% YoY, based on product costs of 14.9% vs 20.6% of revenue
  • Cash and securities $1.15B vs $1.43B at December 31, 2025, with $348.0M operating cash use
  • Outlook: funding expected for at least 12 months, with BRINSUPRI commercialization and TPIP development driving cash needs

Risk Factors

  • No material risk-factor changes identified versus the December 31, 2025 Form 10-K
  • Carried-forward business risk: risks could materially affect financial condition, operations, growth prospects, and common-stock value
  • Carried-forward disclosure risk: actual results may differ materially from forward-looking statements
  • Filing provides no new regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Insmed Incorporated quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.